Abiopharma

🔍 Mulholland Kristen (Executive)

Company: JOHNSON & JOHNSON (JNJ)

Report Date: 2026-02-09

Detailed Transactions and Holdings:

• Acquired 3,602 shares of Performance Share Units (Derivative)
  Date: 2026-02-09 | Code: A | Exercise: 2026-02-13 | equity_swap_involved: 0 | shares_owned_after: 3,602.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2

Footnotes:

• F1: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting.
• F2: The number of PSUs reflects the target number of PSUs originally granted on February 13, 2023, adjusted to reflect achievement relative to the performance conditions set forth in the award agreement, as certified on February 9, 2026.